CDC-RFA-CE-23-0002: Overdose Data to Action in States
Closed
This grant is closed. A newer notice from the same program is open now: NIH, CDC and FDA Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Optional) (PA-27-100). Status: Due dates in the notice, expires April 5, 2027. It is in our archive of Centers for Disease Control - NCIPC notices from 2023.
Centers for Disease Control - NCIPC offered grants of up to $7.0 million (at least $1.4 million) to state and local governments. It expected to make about 51 awards worth $995 million in total. Applications closed on May 8, 2023.
From the official notice on Grants.gov, last changed April 6, 2023. Checked November 7, 2026.
- Award ceiling$7.0 million
- Award floor$1.4 million
- Total funding$995 million
- Expected awards51
- Cost sharingNot required
- Funding typeCooperative Agreement
Key dates
| Posted | March 7, 2023 |
|---|---|
| Deadline | May 8, 2023 |
| Archived by Grants.gov | June 7, 2023 |
Who can apply
This opportunity was open to state and local governments.
- State governments
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Per the statutory language under Section 311 of the PHS Act, PHSA § 311 (c)(1) and the SUPPORT Act this funding opportunity is open to all state health departments (SHDs), including the District of Columbia, or their bona fide agents. CDC is concurrently offering an opportunity tailored to local jurisdictions and territories called Overdose Data to Action: Limiting Overdose through Collaborative Actions in Localities (OD2A: LOCAL; CDC-RFA-CE-23-0003) and also provides funding to tribes or tribal-serving organizations via the cooperative agreement " Strengthening Public Health Systems and Services in Indian Country (CDC-RFA-TO-23-0001),” thereby meeting statutory requirements. Applicants interested in applying for the optional and competitive strategies 4 & 5 must indicate which strategy(ies) they are applying for in the Project Abstract. If they do not specify this, CDC will assume they are not interested in the optional and competitive strategies.
Is this a realistic fit?
- Past Injury Prevention and Control Research and State and Community Based Programs awards averaged $2.2 million; this notice allows up to $7.0 million per award.
- Most of the program's money (76% over five years) went to state and local governments.
- No cost sharing or match is required.
What the grant funds
The Overdose Data to Action in States (OD2A‐S) funding opportunity will be open to all state health departments (SHDs) (includes the District of Columbia) or their bona fide agents. The goal of this funding opportunity is to track nonfatal and fatal overdoses and emerging threats and support SHDs in preventing non‐fatal and fatal overdoses. It will accomplish this through the promotion of overdose surveillance strategies and evidence‐based and promising interventions that have an immediate impact on reducing morbidity and mortality associated with overdoses, with a primary focus on opioids, stimulants, and polysubstance use (if addressed in combination with opioids and stimulants). OD2A‐S will emphasize health equity, and strategies will be underpinned by a data‐to‐action framework that aims to expand and strengthen overdose surveillance efforts of SHDs and their use of these and other data to drive prevention strategies and policies. This funding opportunity builds off the work and gains made through previous overdose surveillance and prevention investments supporting state health departments.
Who has won Injury Prevention and Control Research and State and Community Based Programs grants before
From fiscal 2021 to 2025, Injury Prevention and Control Research and State and Community Based Programs (93.136) awarded $2.2 billion across 986 grant awards, an average of $2.2 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| Florida Department of Health | Florida | 12 | $81.1 million |
| California Department of Public Health | California | 11 | $55.4 million |
| Ohio Department of Health | Ohio | 9 | $42.0 million |
| North Carolina Department of Health & Human Services | North Carolina | 12 | $42.0 million |
| Michigan Department of Health and Human Services | Michigan | 10 | $37.9 million |
Applying now
This notice no longer takes applications. Apply under the newer notice, PA-27-100, which is open now.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is CDC-RFA-CE-23-0002 still open?
No. It closed on May 8, 2023. A newer notice is open: PA-27-100, due dates in the notice, expires April 5, 2027.
Who can apply for Overdose Data to Action in States?
Centers for Disease Control - NCIPC accepted applications from state and local governments. The notice adds further conditions, so read its eligibility section.
What is the deadline for Overdose Data to Action in States?
Closed May 8, 2023. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
Awards of up to $7.0 million each. About $995 million in total across about 51 awards.
Who has won Injury Prevention and Control Research and State and Community Based Programs grants before?
The largest recipients over five fiscal years were Florida Department of Health, California Department of Public Health, Ohio Department of Health. The program made 986 awards worth $2.2 billion in that time.
Similar open grants
- Single Source for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Scientific and Data Research Center (U01 Clinical Trial Required)
- Single Source for the Continuation of the Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Center (Collaborative U01 Clinical Trial Not Allowed)
- Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed)
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)